Webinars

• Engineering modular connectivity in cultured cortical networks using microfluidic devices
• The relationship between network architecture, neural dynamics, and computational capacity
• Autonomous temporal pattern generation through closed-loop reservoir computing
• How living neuronal networks can serve as functional reservoirs for neurocomputing
• The role of HD-MEAs in enabling high-resolution, bidirectional interfacing at scale

• Breakthrough research from MaxWell Biosystems users in neurodevelopment and neurological disease.
• Advances in neuron engineering and molecular analysis.
• How human neural models support development and disease research.
• Approaches linking molecular changes to neuronal function and axonal vulnerability.
• Strategies for generating more diverse and biologically relevant neural cell types in vitro.

• How brain organoids can be used to study network dynamics and functional organization in vitro.
• What it takes to run closed-loop electrophysiology: reading, writing, and feedback-driven training of living networks.
• How HD-MEA functional phenotyping can quantify changes in activity patterns and connectivity over time.
• How organoid bio-model advances translate into biocomputing-style benchmarks and experimental pipelines.
• Practical considerations for implementing these workflows on MaxOne (organoid culture, longitudinal recording, stimulation, and closed-loop interfacing).

• How HD-MEAs can record and characterize photoelectric activity from tellurium nanowire retinal nanoprostheses across visible and near-infrared wavelengths.
• Preclinical use of HD-MEAs to link implant-evoked retinal and cortical activity with restored light sensitivity and behavior in blind animal models.
• The use of HD-MEAs for large-scale ex vivo retinal recordings, enabling population-level monitoring of thousands of neurons for visual scene reconstruction.
• How HD-MEA–generated datasets and analysis pipelines can be used to evaluate and optimize visual prostheses and guide the design of advanced artificial visual systems.

• How the human retina synchronizes visual signals to create a seamless visual experience.
• Groundbreaking findings on the timing precision of visual pathways in the fovea.
• How High-Density Microelectrode Arrays (HD-MEAs) enabled direct measurement of action potential propagation in thousands of human retinal ganglion cells.
• The integration of electrophysiology, anatomical modeling, imaging, and human psychophysics to reveal the retina’s active role in synchronizing perception.
• Insights into how MxW Bio’s HD-MEA technology helps uncover neural computation mechanisms at subcellular resolution.

• A step-by-step demonstration of MaxLab Live’s core features for HD-MEA data visualization, recording, and analysis.
• Practical examples showing how to analyze and interpret electrophysiological data using automated tools.
• Insights on optimizing analysis parameters to extract relevant physiological metrics across various biological preparations.
• An overview of how MaxLab Live helps generate high-quality, publication-ready results with minimal manual processing.

• How combining transcription factoes overexpression with developmental signaling modulation enables the generation of diverse human neuron types.
• Findings from a comprehensive screen of 480 patterning conditions using single-cell transcriptomics on 700,000 cells.
• Functional profiling of neurons using MaxWell Biosystems’ MaxTwo HD-MEA platform to capture activity, connectivity, and morphological diversity across different patterning conditions.
• The relationship between transcriptomic signatures and neuronal structure, revealing mechanisms of maturation and identity formation.

• How the combination of MaxTwo Multi-Well High-Density Multielectrode Arrays (HD-MEA) and FUJIFILM hiPSC-derived neurons has opened new frontiers in investigating neurodegenerative disease mechanisms.
• Comparisons between disease-modeling neuronal lines for Parkinson’s, ALS, and FTD, with healthy donor data highlighting functional differences and disease phenotypes.
• The use of cutting-edge HD-MEA assays under optimized experimental conditions to detect even subtle phenotypic variations and to characterize disease models with greater precision.

‍

• Micro- and nano-channel PDMS platforms enable directional neuronal network fabrication at single-neuron resolution.
• Integration with patient primary or iPSC-derived cells enables precise, personalized disease modeling.
• A biophysical modeling approach coupled with neuronal networks on a chip enables quantification of synaptic receptor alterations in isolated neuronal pairs.
• Application of information theory reveals increased feedback motifs and enhanced information transfer in glioblastoma-infiltrated neuronal networks

• Inter-regional connectivity being key for complex brain functions
• Neural organoid networks serving as in vitro models of inter-regional brain circuits
• HD-MEAs enabling detailed analysis of organoid network activity and functional connectivity

‍

• Human hippocampal tissue slices as a powerful model for studying epileptiform activity
• AAV-mediated optogenetic inhibition of glutamatergic neurons as a strategy to reduce epileptiform activity in human brain networks
• HD-MEA and optogenetics for precise evaluation of network activity in human brain tissue

‍

• iPSC-derived neurons with and without Transactive Response DNA-binding Protein mutations from ALS patients
• HD-MEA insights into functional changes, including hyperactivity and altered network dynamics in mutated neurons
• Foundational knowledge to advance targeted ALS treatment development

• iPSC-derived organoids as a powerful tool to replicate brain development, function, and pathology.
• Exploration of the impact of FGF8 signaling on neocortical identity and glioblastoma invasion.
• The role of HD-MEAs in studying human neuronal organoids and the associated challenges.

• The role of KCNQ2 in neurodevelopment, including the outcomes of this gene mutation.
• Unique network characteristics identified for both KCNQ2 loss- and gain-of-function.
• How these findings can support drug development efforts for KCNQ2 disorders.
• HD-MEA’s contribution to expanding the toolkit for screening new therapies with human-derived in vitro models